Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Rademikibart in Chinese Adults with Moderate to Severe Atopic Dermatitis
NCT05905133Phase 2Active, not recruiting
- Sponsor
- Connect Biopharma
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rademikibart in atopic dermatitis (AD), sponsored by Connect Biopharma. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jul 2023; status: active, not recruiting.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05905133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905133.